[go: up one dir, main page]

NO20084850L - MGLUR5 modulatorer I - Google Patents

MGLUR5 modulatorer I

Info

Publication number
NO20084850L
NO20084850L NO20084850A NO20084850A NO20084850L NO 20084850 L NO20084850 L NO 20084850L NO 20084850 A NO20084850 A NO 20084850A NO 20084850 A NO20084850 A NO 20084850A NO 20084850 L NO20084850 L NO 20084850L
Authority
NO
Norway
Prior art keywords
mglur5 modulators
novel compounds
mglur5
modulators
preparation
Prior art date
Application number
NO20084850A
Other languages
English (en)
Norwegian (no)
Inventor
Abdelmalik Slassi
Tao Xin
Tomislav Stefanac
Louise Edwards
Bjorn Holm
Karolina Nilsson
Methvin Isaac
Andreas Wallberg
Mats Nagard
Kenneth Granberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084850L publication Critical patent/NO20084850L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20084850A 2006-05-05 2008-11-18 MGLUR5 modulatorer I NO20084850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79765906P 2006-05-05 2006-05-05
PCT/US2007/067367 WO2007130820A2 (en) 2006-05-05 2007-04-25 Mglur5 modulators i

Publications (1)

Publication Number Publication Date
NO20084850L true NO20084850L (no) 2008-12-02

Family

ID=38668440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084850A NO20084850L (no) 2006-05-05 2008-11-18 MGLUR5 modulatorer I

Country Status (19)

Country Link
US (1) US7678796B2 (es)
EP (1) EP2027120A2 (es)
JP (1) JP2009536209A (es)
KR (1) KR20090009952A (es)
CN (1) CN101506202A (es)
AR (1) AR060651A1 (es)
AU (1) AU2007248288A1 (es)
BR (1) BRPI0710979A2 (es)
CA (1) CA2650114A1 (es)
CL (1) CL2007001174A1 (es)
CO (1) CO6140060A2 (es)
EC (1) ECSP088864A (es)
IL (1) IL194814A0 (es)
MX (1) MX2008013835A (es)
NO (1) NO20084850L (es)
RU (1) RU2008141509A (es)
TW (1) TW200811157A (es)
UY (1) UY30304A1 (es)
WO (1) WO2007130820A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1918154A (zh) * 2004-02-18 2007-02-21 阿斯利康(瑞典)有限公司 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
GEP20125425B (en) * 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
WO2009023721A1 (en) 2007-08-13 2009-02-19 Divergence, Inc. Compositions and methods for controlling nematodes
CL2008003085A1 (es) 2007-10-19 2009-10-09 Astrazeneca Ab Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
EA201000656A1 (ru) * 2007-10-26 2010-12-30 Астразенека Аб Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054792A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Aminopyridine derivatives as modulators of mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
WO2009054789A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
CN102285914B (zh) * 2010-06-18 2013-12-25 上海药明康德新药开发有限公司 2-(1-甲基-6-羰基-1,6-二氢-吡啶)-乙酸的合成方法
BR112013005136B1 (pt) 2010-09-02 2018-03-20 Monsanto Technology Llc Compostos e composições nematicidas, bem como métodos para controlar pragas de nematódeo
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
GB201215033D0 (en) * 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives
BR112015006218A2 (pt) * 2012-09-27 2017-07-04 Hoffmann La Roche derivados de ariletinil
AR095330A1 (es) 2013-03-15 2015-10-07 Monsanto Technology Llc Azoles n-,c-disustituidos y composiciones y métodos para controlar plagas de nematodos
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
CA3075892C (en) * 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506340A (ja) 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
EP1581525A2 (en) 2002-08-09 2005-10-05 AstraZeneca AB Compounds having an activity at metabotropic glutamate receptors
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
CN1918154A (zh) * 2004-02-18 2007-02-21 阿斯利康(瑞典)有限公司 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1716125B1 (en) 2004-02-18 2013-06-19 AstraZeneca AB Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
BRPI0507495A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
WO2006048771A1 (en) * 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0514296D0 (en) 2005-07-12 2005-08-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2007130820A2 (en) 2007-11-15
RU2008141509A (ru) 2010-06-20
AU2007248288A1 (en) 2007-11-15
JP2009536209A (ja) 2009-10-08
AR060651A1 (es) 2008-07-02
ECSP088864A (es) 2008-12-30
CL2007001174A1 (es) 2008-01-18
CA2650114A1 (en) 2007-11-15
TW200811157A (en) 2008-03-01
KR20090009952A (ko) 2009-01-23
MX2008013835A (es) 2008-11-10
IL194814A0 (en) 2009-08-03
UY30304A1 (es) 2007-11-30
BRPI0710979A2 (pt) 2011-05-31
CO6140060A2 (es) 2010-03-19
US7678796B2 (en) 2010-03-16
US20070259862A1 (en) 2007-11-08
WO2007130820A3 (en) 2008-03-13
EP2027120A2 (en) 2009-02-25
CN101506202A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
NO20084850L (no) MGLUR5 modulatorer I
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20084852L (no) MGLUR5 modulatorer V
NO20090628L (no) Pyridizinon derivativater
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20084712L (no) Nye farmasoytiske forbindelser
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
NO20081479L (no) 7-(2-Amino-1-hydroksyetyl)-4-hydroksybenzotiazol-2(3H)-ondenvater som beta2-adrenoceptoragonister
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
NO20090295L (no) Substituerte heteroarylderivater
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008115281A3 (en) Compounds for treating viral infections
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
NO20081217L (no) Nye benzotiazolonderivater
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20091626L (no) MGLUR5-modulatorer
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY30307A1 (es) Moduladores de mglur5 vi
WO2007130822A3 (en) Mglur5 modulators iii
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application